Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

This is a phase III clinical trial that aims to evaluate whether increasing the dose of radiotherapy given twice a day can improve treatment outcomes in patients with localized small cell lung cancer (SCLC). All patients will receive standard chemotherapy with cisplatin and etoposide and will be randomly assigned to one of three radiotherapy regimens. The main objective is to determine whether this intensified radiotherapy improves progression-free survival and overall survival. The study will also compare two different dose escalation strategies and assess treatment side effects and patients

Trial Details

NCT ID
NCT07015892
Phase
PHASE3
Sponsor
Instituto de Investigación Biomédica de Salamanca
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Thoracic Radiotherapy 45 Gy BID
  • Thoracic Radiotherapy 60 Gy BID
  • Thoracic Radiotherapy SIB 45-54 Gy BID
Locations (sample)
  • Salamanca, Salamanca, Spain|40.96882,-5.66388
  • Almería, Spain|36.83814,-2.45974
  • Barakaldo, Spain|43.29639,-2.98813
  • Girona, Spain|41.98311,2.82493
  • Las Palmas de Gran Canaria, Spain|28.10178,-15.41573

Key Eligibility Criteria

  • Histologically confirmed diagnosis of small cell lung cancer (SCLC)
  • Limited-stage disease (Stage I-III; any T, any N, M0), eligible for definitive radiotherapy
  • Measurable disease according to RECIST 1.1
  • Age ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →